2B77.DE vs. CURE.DE
2B77.DE (iShares Ageing Population UCITS ETF) and CURE.DE (VanEck Genomics and Healthcare Innovators UCITS ETF A) are both Health & Biotech Equities funds - 2B77.DE tracks the iSTOXX® FactSet Ageing Population while CURE.DE tracks the MVIS Global Future Healthcare ESG. Both are passively managed. Over the past 3 years, 2B77.DE returned 14.15%/yr vs -0.09%/yr for CURE.DE. A 0.70 correlation means they provide meaningful diversification when combined. 2B77.DE charges 0.40%/yr vs 0.35%/yr for CURE.DE.
Performance
2B77.DE vs. CURE.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, 2B77.DE achieves a 9.52% return, which is significantly higher than CURE.DE's 0.01% return.
2B77.DE
- 1D
- 0.34%
- 1M
- 5.65%
- YTD
- 9.52%
- 6M
- 9.39%
- 1Y
- 25.81%
- 3Y*
- 14.15%
- 5Y*
- 6.04%
- 10Y*
- —
CURE.DE
- 1D
- 0.00%
- 1M
- 11.67%
- YTD
- 0.01%
- 6M
- -0.48%
- 1Y
- 14.68%
- 3Y*
- -0.09%
- 5Y*
- —
- 10Y*
- —
2B77.DE vs. CURE.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
2B77.DE iShares Ageing Population UCITS ETF | 9.52% | 13.28% | 14.40% | 5.16% | -4.15% |
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | 0.01% | 5.09% | 0.30% | -6.42% | -3.30% |
Correlation
The correlation between 2B77.DE and CURE.DE is 0.65, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.65 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.69 |
Correlation (All Time) Calculated using the full available price history since Sep 7, 2022 | 0.70 |
The correlation between 2B77.DE and CURE.DE has been stable across timeframes, ranging from 0.65 to 0.70 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
2B77.DE vs. CURE.DE — Risk / Return Rank
2B77.DE
CURE.DE
2B77.DE vs. CURE.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Ageing Population UCITS ETF (2B77.DE) and VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| 2B77.DE | CURE.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.40 | ||
| Sortino ratioReturn per unit of downside risk | +1.82 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.13 | +0.24 |
| Calmar ratioReturn relative to maximum drawdown | 3.80 | 0.77 | +3.03 |
| Martin ratioReturn relative to average drawdown | 13.40 | 1.66 | +11.74 |
Loading charts...
Drawdowns
2B77.DE vs. CURE.DE - Drawdown Comparison
The maximum 2B77.DE drawdown since its inception was -38.55%, which is greater than CURE.DE's maximum drawdown of -34.80%. Use the drawdown chart below to compare losses from any high point for 2B77.DE and CURE.DE.
Loading charts...
Drawdown Indicators
| 2B77.DE | CURE.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.55% | -34.80% | -3.75% |
Max Drawdown (1Y)Largest decline over 1 year | -6.76% | -19.07% | +12.31% |
Max Drawdown (3Y)Largest decline over 3 years | -20.13% | -29.29% | +9.16% |
Max Drawdown (5Y)Largest decline over 5 years | -20.13% | — | — |
Current DrawdownCurrent decline from peak | 0.00% | -11.12% | +11.12% |
Average DrawdownAverage peak-to-trough decline | -6.96% | -15.12% | +8.16% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 1.92% | 8.87% | -6.95% |
Volatility
2B77.DE vs. CURE.DE - Volatility Comparison
The current volatility for iShares Ageing Population UCITS ETF (2B77.DE) is 3.17%, while VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) has a volatility of 7.10%. This indicates that 2B77.DE experiences smaller price fluctuations and is considered to be less risky than CURE.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| 2B77.DE | CURE.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 3.17% | 7.10% | -3.93% |
Volatility (6M)Calculated over the trailing 6-month period | 9.22% | 15.59% | -6.37% |
Volatility (1Y)Calculated over the trailing 1-year period | 12.13% | 20.41% | -8.28% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 15.12% | 20.75% | -5.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 17.80% | 20.75% | -2.95% |
2B77.DE vs. CURE.DE - Expense Ratio Comparison
2B77.DE has a 0.40% expense ratio, which is higher than CURE.DE's 0.35% expense ratio.
Dividends
2B77.DE vs. CURE.DE - Dividend Comparison
Neither 2B77.DE nor CURE.DE has paid dividends to shareholders.
Frequently Asked Questions
2B77.DE and CURE.DE have a correlation of 0.65, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, CURE.DE is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
CURE.DE is cheaper with a 0.35% expense ratio, compared with 0.40% for 2B77.DE.
2B77.DE tracks iSTOXX® FactSet Ageing Population, while CURE.DE tracks MVIS Global Future Healthcare ESG. They also come from different issuers: iShares and VanEck. Their fees differ too: 0.40% for 2B77.DE and 0.35% for CURE.DE.
Find the right allocation for 2B77.DE and CURE.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer